Targeted Oncology38m
Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion
The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...
Targeted Oncology1h
Patient Case 2: A 65-Year-Old Patient With Standard-Risk, Transplant-Eligible NDMM
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...
Targeted Oncology1h
IMROZ Data Highlights and Clinical Insights Into Quadruplet CD38-Containing Regimens in Transplant-Ineligible NDMM
Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...
Targeted Oncology18h
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline Gastric/GEJ/Esophageal Cancer
CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Targeted Oncology18h
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...
Targeted Oncology18h
Lean Six Sigma in Oncology: Insights From Waterhouse and Mendenhall
David M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed ...
Targeted Oncology18h
Evaluating Fedratinib in Rare Myeloproliferative Diseases
Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...